Article Text

Download PDFPDF
Comparative Study of Tamoxifen and Raloxifene on Endometrial Cell Proliferation of Female Rats in Persistent Estrus
  1. Dorival Mendes Rodrigues Junior, MD,
  2. Alesse Ribeiro dos Santos, MD,
  3. Pedro Vitor Lopes Costa, MD, PhD and
  4. Benedito Borges da Silva, MD, PhD
  1. Department of Gynecology, Federal University of Piaui, Teresina, Piaui, Brazil.
  1. Address correspondence and reprint requests to Dorival Mendes Rodrigues Junior, Department of Gynecology, Federal University of Piaui, Avenida Dom Severino, 2600 apto 604, 64049-375 Teresina, Piaui, Brazil. E-mail: dorivalmrjr{at}


Objective The objective of the study was to compare the effect of tamoxifen and raloxifene on the endometrium of female rats in persistent estrus, by Ki-67 protein expression.

Methods The study comprised 60 Wistar-Hannover female rats in persistent estrus, induced by a single subcutaneous dose of 1.25 mg of testosterone propionate on the second day of age. At 90 days of life, the animals were randomly divided into 3 groups of 20 animals each. Group 1 (control), received only placebo; group 2, the animals were treated with tamoxifen, 250 μg/d; and group 3, the rats were treated with 750 μg/d of raloxifene by gavage during 30 days. Then, the animals were killed, and the endometrium was removed for immunohistochemical analysis of Ki-67 antigen expression. Statistical analysis was performed by β regression model (P < 0.05).

Results Mean percentages of Ki-67 protein expression in the endometrium of rats in persistent estrus were 43.21% ± 3.39%, 7.36% ± 0.95%, and 7.20% ± 0.76% in groups 1, 2 and 3, respectively (P < 0.001). There was no statistical difference between groups 2 and 3 (P = 0.7159).

Conclusions The present results indicate that, at the doses and during the time of treatment used, both tamoxifen and raloxifene induce atrophy in a similar way of endometrial epithelium of rats in persistent estrus.

  • Endometrium
  • Ki-67
  • Persistent estrus
  • Raloxifene
  • Tamoxifen

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors report no conflict of interest.